Spotlight
Commentary
Cultural Corner
Psychiatric Practice
Series
News
Job Board
CME/CE
Partners
Editorial
Subscribe
Video
Sharing the Results: ALKS 3831
Author(s):
ALKS 3831, if approved by the FDA, could be a promising new treatment option for schizophrenia or bipolar I disorder.
Adam Simmons, MPH, shares results and insights from the Enlightened II study for Alkermes' drug, ALKS 3831.
To read more about ALKS 3831, see FDA Advisory Committee Votes in Favor of ALKS 3831.
Mr Simmons is the Director of Clinical Program Management at Alkermes.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
Related Videos
Related Content
